<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> often occurs in association with <z:hpo ids='HP_0000822'>hypertension</z:hpo> and <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e>, and markedly increases cardiovascular risk </plain></SENT>
<SENT sid="1" pm="."><plain>Strategies to reduce the incidence of <z:mp ids='MP_0002055'>diabetes</z:mp> in patients with <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> or at high risk for such disease are therefore important </plain></SENT>
<SENT sid="2" pm="."><plain>Certain classes of <z:chebi fb="0" ids="35674">antihypertensive agents</z:chebi>, namely the <z:chebi fb="0" ids="50264">thiazide</z:chebi> <z:chebi fb="40" ids="35498">diuretics</z:chebi> and beta-blockers, have an adverse impact on the metabolic profile and increase the risk for new-<z:hpo ids='HP_0003674'>onset</z:hpo> <z:mp ids='MP_0002055'>diabetes</z:mp> in hypertensive subjects </plain></SENT>
<SENT sid="3" pm="."><plain>In contrast, angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), which are blockers of the renin-angiotensin system (<z:mp ids='MP_0011356'>RAS</z:mp>), have been shown to increase insulin sensitivity </plain></SENT>
<SENT sid="4" pm="."><plain>They may also reduce the risk of <z:mp ids='MP_0002055'>diabetes</z:mp> in patients with <z:hpo ids='HP_0000822'>hypertension</z:hpo> or <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disorders</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Some of the evidence in favour of <z:chebi fb="2" ids="35457">ACE inhibitors</z:chebi> and ARBs has come from studies with active comparators that have potential adverse metabolic effects </plain></SENT>
<SENT sid="6" pm="."><plain>However, the <z:chebi fb="0" ids="3347">Candesartan</z:chebi> in <z:hpo ids='HP_0001635'>Heart failure</z:hpo>-Assessment of Reduction in Mortality and morbidity (CHARM) programme demonstrated that the ARB <z:chebi fb="0" ids="3347">candesartan</z:chebi> reduced the incidence of <z:mp ids='MP_0002055'>diabetes</z:mp> in <z:hpo ids='HP_0001635'>heart failure</z:hpo> patients in comparison to placebo </plain></SENT>
<SENT sid="7" pm="."><plain>The mechanisms responsible for the beneficial effects of <z:mp ids='MP_0011356'>RAS</z:mp> blockade remain to be established </plain></SENT>
<SENT sid="8" pm="."><plain>Nevertheless, a treatment that can control <z:hpo ids='HP_0000822'>hypertension</z:hpo> and reduce the risk of <z:hpo ids='HP_0003674'>onset</z:hpo> of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> at the same time is certainly desirable </plain></SENT>
</text></document>